Affection of short-term and low-dose glucocorticoid on bone mineral density and bone metabolism in the treatment of male patients with ankylosing spondylitis
Department of Rheumatism, the People’s Hospital of Fuyang, Hangzhou, 311400
WEN Li,WANG Guoliang,SHENG Tongliang, et al. Affection of short-term and low-dose glucocorticoid on bone mineral density and bone metabolism in the treatment of male patients with ankylosing spondylitis[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(11): 835-.
Abstract：Objective: Explore the change of bone mineral density and bone metabolism in male patients with ankylosing spondylitis by short-term and low-dose glucocorticoid. Methods: Randomly divide 46 patients into non-GC treatment group (22) and low-dose GC treatment group (24). Non-GC treatment group receive DMARD and Ca, Low-dose GC treatment group receive low dose glucocorticoid as well as DMARD and Ca. The Serum levels of osteoprotegerin (OPG), macrophage-colony stimulating factors (M-CSF), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), bath AS disease activity index (BASDAI) and Bone mineral density (BMD) were measured at the baseline and 6 months after therapy. Results: Six months after treatment, the level of OPG increased significantly (P<0.05) and the level of ESR, CRP, BASDAI decreased significantly (P<0.05) in both groups respectively, compared with that at the baseline; the level of M-CSF of two treatment groups decreased, in which the low-dose GC treatment group did more significantly (P<0.05). Six months after treatment, there was no significant difference in the levels of OPG, M-CSF, and BMD (P<0.05) between the two groups. There was significant difference in the levels of ESR, CRP, BASDAI between the two groups (P>0.05).Conclusion: Short-term treatment of low-dose GC affect bone metabolisms and inflamed index, while with no significant influence on BMD in AS patients. It is safe and benefit for AS patients.
